Therapeutic Response

CD20 + status confers therapeutic sensitivity to Gemcitabine in combination with Oxaliplatin and Rituximab in patients with Non-Hodgkin Lymphoma.

Statements

Source and description
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with gemcitabine and oxaliplatin for reimbursement as a treatment option for the treatment of relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.